Xcout Intel
ZyVersa Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to ZyVersa Therapeutics, Inc. among biotech companies — ranked by similarity to what ZyVersa Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see ZyVersa Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
ZyVersa Therapeutics, Inc. at a glance
ZyVersa Therapeutics, Inc. is a biotech company headquartered in Weston, United States. It is publicly listed (ZVSA) with a market capitalisation of $939,127. Xcout tracks 16 named people at ZyVersa Therapeutics, Inc., including Peter Wolfe (Chief Financial Officer & Secretary).
ZyVersa Therapeutics, Inc. leadership
- Peter WolfeChief Financial Officer & Secretary
- Karen A. CashmereChief Commercial Officer
- Stephen C. GloverCo-Founder, Chairman, Chief Executive Officer & President
- Christopher TwittyDirector
- Daniel J. O'ConnorDirector
- David S. BrionesDirector
10 more named people on record for ZyVersa Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Top 12 ZyVersa Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to ZyVersa Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
ENYO Pharma is a clinical-stage biopharmaceutical company that develops therapeutics for patients with impaired kidney function. Its lead compound, Vonafexor, is a small molecule currently in Phase 2 development to treat rare kidney diseases such as Alport syndrome and chronic kidney disease.
Biotechnology
Rezera Inc., formerly known as NodThera, is advancing oral anti-inflammatory NLRP3 inhibitors, including the Ruvonoflast Phase 3 development program, with headquarters in Boston.
Biotechnology
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney diseases, including specific pipeline candidates for gout and other conditions.
Biotechnology
Inversago Pharma is a Canadian biotechnology company developing peripherally restricted CB1 receptor antagonists/inverse agonists for metabolic, fibrotic, and related diseases. Its drug-development programs are intended to serve patients with conditions such as obesity, metabolic syndrome, and diabetic kidney disease.
Biotechnology
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Biotechnology
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Similar biotech company
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Biotechnology
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Similar biotech company
Iterion Therapeutics is a clinical-stage biopharmaceutical company headquartered in Houston, Texas. Founded in 2015, the company is dedicated to revolutionizing healthcare through novel drug discovery and innovation.
Biotechnology
Forward Therapeutics, Inc. is a biotechnology company headquartered in Palm Beach Gardens, Florida, United States, advancing a data-driven pipeline of oral small molecule therapies for inflammation-driven diseases.
Similar biotech company
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Biotechnology
Aegle Therapeutics Corp. is a clinical-stage biotechnology company headquartered in Miami, Florida, with additional operations in Woburn, Massachusetts. The company is a leader in developing novel extracellular vesicle therapies to treat various diseases and disorders.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ZyVersa Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ZyVersa Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →